On August 28, the Food and Drug Administration (FDA) expanded its approval of the estrogen-blocking drug fulvestrant (Faslodex®) for some women with advanced breast cancer. The new
Type 2 diabetics are known to have greater risk of cardiovascular complications compared to those without the condition. Due to this risk, the FDA will
Researchers from the University of Leicester have identified a new protein involved in airway inflammation in patients with severe asthma. The results from their study
Results from a phase I trial conducted by Alnylam Pharmaceuticals suggest that a new drug class may be available to help manage patients’ cholesterol levels.
We conducted an interview with the CEO of Osprey Medical, Mike McCormick, on Wednesday, 1 February 2017. Company name: Osprey Medical (based in Minnesota, USA)
In January 2017, a US Federal Court ordered a ban on the sale of Praluent, a PCSK9 inhibitor (used for lowering cholesterol) developed by pharmaceutical
